二、监事会会议审议情况 会议审议并通过了如下议案： 1、《关于继续使用部分闲置募集资金和自有资金进行现金管理的议案》 证券代码：301211 证券简称：亨迪药业 公告编号：2024-008 湖北亨迪药业股份有限公司 第二届监事会第四次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届监事会第四次会议 于 2023 年 12 月 28 日以电话及邮件方式送达至全体监事，本会议于 2024 年 1 月 3 日以现场方式召开。本次会议应参会监事 3 人，实际参会监事 3 人。会议由 监事会主席全俊先生召集并主持。本次会议的召集、召开和表决程序符合《中华 人民共和国公司法》和《公司章程》的有关规定，会议合法、有效。 在确保不影响募集资金投资项目建设和公司正常生产经营的前提下，拟继续 使用不超过人民币50,000.00万元闲置募集资金和不超过人民币40,000.00万元自 有资金进行现金管理，使用期限自股东大会审议通过之日起 12 个月内有效。在 上述额度和期限内，资金可循环滚动使用 ...

国泰君安证券股份有限公司 关于湖北亨迪药业股份有限公司 首次公开发行部分限售股上市流通的核查意见 国泰君安证券股份有限公司（以下简称"国泰君安"或"保荐机构"）作为 湖北亨迪药业股份有限公司（以下简称"亨迪药业"或"公司"）首次公开发行 股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等相关规定，对亨迪药业首次公开发行部分限售股份上市流 通的事项进行了审慎核查，具体核查情况如下： 一、本次上市流通的限售股类型 经中国证券监督管理委员会证监许可[2021]3639 号文核准，亨迪药业向社会 公开发行人民币普通股（A 股）6,000.00 万股，于 2021 年 12 月 22 日在深圳证券 交易所上市交易。公司首次公开发行股票后，总股本由 18,000 万股变更为 24,000 万股。其中无限售条件流通股为 54,767,687 股，占发行后总股本的比例为 22.82%， 有限售条件流通股为 185,232,313 股，占 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2023-052 湖北亨迪药业股份有限公司 关于首次公开发行部分限售股 上市流通提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整， 不存在任何虚假记载、误导性陈述或者重大遗漏。 特别提示： 1、本次上市流通的限售股为公司首次公开发行战略配售限售股。本次申请解除 股份限售的股东为国泰君安证裕投资有限公司，解除限售股份的数量为 2,790,697 股，占公司总股本的 0.969%。 2、本次解除限售股份限售起始日期为 2021 年 12 月 22 日，限售期限为自公司股 票上市之日起 24 个月，上市流通日期为 2023 年 12 月 22 日。 一、本次上市流通的限售股类型 经中国证券监督管理委员会证监许可[2021]3639 号文核准，亨迪药业向社会 公开发行人民币普通股（A 股）6,000.00 万股，于 2021 年 12 月 22 日在深圳证券 交易所上市交易。公司首次公开发行股票后，总股本由 18,000 万股变更为 24,000 万股。其中无限售条件流通股为 54,767,687 股，占发行后总股本的比例为 22.82%， 有限售条 ...

关于湖北亨迪药业股份有限公司 2023 年度持续督导培训情况的工作报告 根据《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》，国 泰君安证券股份有限公司（以下简称"国泰君安"、"保荐机构"）作为湖北亨 迪药业股份有限公司（以下简称"亨迪药业"、"公司"）持续督导的保荐机构， 于 2023 年 12 月 1 日对公司董事、监事、高级管理人员、中层以上管理人员及公 司实际控制人等相关人员进行了持续督导培训。 国泰君安证券股份有限公司 实施本次现场培训前，国泰君安编制了培训材料，并提前要求亨迪药业参与 培训的相关人员了解培训相关内容。 公司实际控制人、董事、监事、高级管理人员及部分中层以上管理人员参加 了本次培训。 二、本次持续督导培训的主要内容 本次培训主要内容为《深圳证券交易所创业板股票上市规则》《上市公司监 管指引第 2 号——上市公司募集资金管理和使用的监管要求》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规，内容 包括募集资金管理、关联交易、股份锁定与减持、信息披露规则、对外担保、内 幕信息管理、并购重组等相关规定以及上市公司违规案例等。 现将本次培训 ...

国泰君安证券股份有限公司 关于湖北亨迪药业股份有限公司 2023 年度持续督导工作定期现场检查报告 | 保荐机构名称：国泰君安证券股份有限公司 | 被保荐公司简称：亨迪药业 | | | --- | --- | --- | | 保荐代表人姓名：李懿 | 联系电话：021-38676515 | | | 保荐代表人姓名：王栋 | 联系电话：021-38677593 | | | 现场检查人员姓名：李懿、王慷 | | | | 现场检查对应期间：2023年度 | | | | 现场检查时间：2023年12月1日 | | | | 一、现场检查事项 | 现场检查意见 | | | 是 （一）公司治理 | 否 | 不适用 | | 现场检查手段： | | | | （1）访谈公司相关董事、监事、高管人员； | | | | （2）检查公司三会会议文件； | | | | （3）核查董事会专业委员会文件及核对公司相关公告； | | | | （4）查阅公司章程以及其他治理制度的相关文件； | | | | （5）核查公司就有关事项出具的说明。 | | | | 1.公司章程和公司治理制度是否完备、合规 √ | | | | 2.公司章程和三会规则是 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2023-051 湖北亨迪药业股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 湖北亨迪药业股份有限公司（以下简称"公司"）于 2023 年 4 月 24 日召开第一届董事会第十七次会议、第一届监事会第十一次会 议，并于 2023 年 5 月 19 日召开了 2022 年年度股东大会，审议通过 了《关于续聘公司 2023 年度审计机构的议案》，续聘大信会计师事 务所（特殊普通合伙）（以下简称"大信会计师事务所"）为公司 2023 年度的审计机构。具体内容详见公司 2023 年 4 月 25 日、2023 年 5 月 19 日披露于巨潮资讯网（http://www.cninfo.com.cn）的相 关公告。 公司于近日收到大信会计师事务所出具的《关于变更 2023 年度 审计签字注册会计师的告知函》，现将具体情况公告如下： 潘杨州先生，拥有注册会计师，具有证券业务服务经验，2014 年取得注册会计师职业资格，从 2012 年至今在大信会计师事务所（特 殊普通合伙）从 ...

Financial Performance - The net profit for the third quarter of 2023 reached CNY 144,514,979.02, a significant increase of 83.83% compared to CNY 78,551,187.11 in the same period last year[3] - The company reported an operating profit of CNY 171,168,058.78, which is a 83% increase from CNY 93,606,855.47 in the previous year[3] - Operating revenue increased by 56.93% to CNY 542,445,746.24 from CNY 345,656,815.72 in the same period last year[31] - Total operating revenue for the third quarter reached ¥542,445,746.24, a significant increase from ¥345,656,815.72 in the same period last year, representing a growth of approximately 56.9%[43] - Basic and diluted earnings per share for the quarter were both ¥0.50, compared to ¥0.27 in the previous year, reflecting an increase of approximately 85.2%[39] - The net profit attributable to shareholders for the current period is CNY 31,476,110.61, reflecting a 30.32% increase year-over-year[48] - The net profit attributable to shareholders after deducting non-recurring gains and losses is CNY 30,899,063.90, which is a 45.57% increase compared to the previous year[48] Assets and Equity - The total assets as of September 30, 2023, amounted to CNY 2,498,883,170.39, slightly up from CNY 2,497,721,443.51 at the beginning of the year[1] - The company's total equity attributable to shareholders increased to CNY 2,326,723,462.93 from CNY 2,276,499,452.63, reflecting a growth of 2.2%[1] - Non-current assets totaled CNY 379,696,150.53, while total assets reached CNY 2,498,883,170.39, compared to CNY 270,826,069.16 and CNY 2,497,721,443.51 respectively in the previous year[19] - The total assets at the end of the reporting period amount to CNY 2,498,883,170.39, a slight increase of 0.05% from the end of the previous year[48] - The equity attributable to shareholders at the end of the reporting period is CNY 2,326,723,462.93, which is a 2.21% increase from the previous year[48] Cash Flow - Cash and cash equivalents at the end of the third quarter were CNY 1,729,396,597.93, down from CNY 1,858,088,871.05 at the beginning of the year, indicating a decrease of 6.9%[5] - Cash flow from operating activities decreased by 32.99% to CNY 82,988,321.06, primarily due to significant pre-receipts in December 2022[31] - The net cash flow from operating activities for the year-to-date is CNY 82,988,321.06, showing a decrease of 32.99% compared to the same period last year[48] - The cash inflow from investment activities for the current period is CNY 377,510.89, compared to CNY 63,000.00 in the previous period[48] Expenses - R&D expenses surged by 131.24% to CNY 34,932,093.15, driven by the company's integrated strategy of "raw materials + formulations" and progress in consistency evaluation[31] - Total operating costs amounted to ¥374,327,664.34, up from ¥261,859,834.81, indicating an increase of about 42.7% year-over-year[43] - Tax expenses for the quarter were ¥4,467,473.08, up from ¥2,280,330.08, representing an increase of approximately 96.2% year-over-year[43] - Sales expenses increased to ¥17,471,902.46 from ¥13,790,374.69, reflecting a rise of about 26.5%[43] - Management expenses decreased slightly to ¥35,340,769.90 from ¥37,409,148.74, showing a reduction of approximately 5.5%[43] Shareholder Information - The company’s total number of common shareholders at the end of the reporting period was 24,588[33] - The largest shareholder, Shanghai Yongda Sheng Business Consulting Co., Ltd., holds a 38.25% stake, amounting to 110,160,000 shares[33] Liabilities - The total liabilities amounted to CNY 172,159,707.46, compared to CNY 221,221,990.88 in the previous year[19] - Contract liabilities decreased by 81.79% to CNY 12,692,792.18 from CNY 69,720,405.61 in the previous year[31] Audit Status - The company has not undergone an audit for the third quarter report[24]

具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2023 年第三季度报告》（公告编号：2023-048）。 证券代码：301211 证券简称：亨迪药业 公告编号：2023-050 湖北亨迪药业股份有限公司 第二届监事会第三次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届监事会第三次会议 于 2023 年 10 月 13 日以电话及邮件方式送达至全体监事，本会议于 2023 年 10 月 17 日以现场方式召开。本次会议应参会监事 3 人，实际参会监事 3 人。会议 由监事会主席全俊先生召集并主持。本次会议的召集、召开和表决程序符合《中 华人民共和国公司法》和《公司章程》的有关规定，会议合法、有效。 二、监事会会议审议情况 会议审议并通过了如下议案： 1、《2023 年第三季度报告》 表决结果：3 票同意、0 票反对、0 票弃权。该项议案获审议通过。 2、关于对 2023 年第三季度报告的审核意见的议案 经审议，监事会认为董事会编制和审核的公 ...

本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 证券代码：301211 证券简称：亨迪药业 公告编号：2023-049 湖北亨迪药业股份有限公司 第二届董事会第三次会议决议公告 湖北亨迪药业股份有限公司（以下简称"公司"）第二届董事会第三次会议 于 2023 年 10 月 13 日以电话及邮件方式送达至全体董事，会议于 2023 年 10 月 17 日以现场和通讯方式召开。本次会议应参会董事 8 人，实际参会董事 8 人， 其中现场出席会议的董事 3 人，董事黄雪强、朱晓兵，独立董事项光亚、傅仁辉、 姚克以通讯方式参加会议。会议由公司董事长程志刚主持，公司监事和高级管理 人员列席会议。本次董事会会议的召集、召开和表决程序符合《中华人民共和国 公司法》等法律法规和《公司章程》的有关规定，会议合法、有效。 二、董事会会议审议情况 会议审议并通过了如下议案： 1、《2023 年第三季度报告》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2023 年第三季度报告》。（公告编号：2023-048） 表决结果：赞 ...

Financial Performance - The company's operating revenue for the reporting period reached ¥405,758,580.58, representing a 68.80% increase compared to the previous year[2]. - Net profit attributable to shareholders was ¥113,038,868.41, marking a 107.80% increase year-over-year[2]. - The basic earnings per share increased to ¥0.39, up 105.26% from the previous year's ¥0.23[2]. - The total assets at the end of the reporting period were ¥2,492,507,929.66, showing a slight decrease of 0.21% from the previous year[2]. - The net assets attributable to shareholders increased to ¥2,294,547,429.95, reflecting a 0.79% growth compared to the previous year[2]. - The net cash flow from operating activities was ¥47,336,095.03, which is a decrease of 48.80% from the previous year[2]. - The company's revenue for the reporting period reached ¥405,758,580.58, a year-on-year increase of 68.80%, primarily due to increased domestic sales of raw materials and related formulations[38]. - The cost of sales amounted to ¥245,874,842.46, reflecting a year-on-year increase of 43.70%, attributed to the same factors driving revenue growth[38]. - Research and development expenses surged by 110.62% to ¥20,214,826.43, as the company actively advanced its "raw materials + formulations" integration strategy[38]. - The company reported a significant increase in sales expenses, which rose by 44.87% to ¥13,372,479.14, driven by intensified marketing efforts[38]. Industry and Market Position - The company operates in the pharmaceutical manufacturing industry, focusing on chemical drug raw materials and formulations[11]. - The company focuses on the research, production, and sales of chemical raw materials (including intermediates) and formulations, and offers contract development and manufacturing services (CDMO) based on customer needs[13]. - The company has achieved significant recognition, being a qualified global supplier for major pharmaceutical companies such as Sanofi, GlaxoSmithKline, and Abbott, with products registered in over 80 countries[17]. - The company is recognized as a high-tech enterprise in Hubei Province, continuously investing in new technologies, processes, and product development[17]. - The company is committed to high-quality development in the pharmaceutical manufacturing sector, supported by national policies aimed at enhancing drug supply security and innovation[12]. Product Development and Innovation - The company emphasizes the development of children's medications and rare disease drugs, aligning with national policies to encourage innovation in these areas[12]. - The company is advancing the research and development of new formulations, including sustained-release capsules and enteric-coated capsules[29]. - The company is focusing on innovative production processes to reduce costs and improve efficiency, thereby enhancing its competitive edge[32]. - The company has developed a series of Ibuprofen derivative products to meet diverse customer needs and expand market reach[29]. - The company has successfully passed the FDA certification and is registered in multiple countries including the US and EU[22]. Environmental Compliance and Safety - The company has a wastewater treatment capacity of 3,000 tons per day, ensuring compliance with discharge standards of COD ≤ 657 mg/L and ammonia nitrogen ≤ 114 mg/L[128][130]. - The company has established a centralized exhaust gas treatment facility with a capacity of 260,000 cubic meters per hour, adhering to the GB37823-2019 emission standards[131]. - The company has committed to environmental compliance, with all wastewater and waste gas emissions meeting regulatory standards[126][128]. - The company has implemented various technologies for waste gas treatment, including membrane absorption and carbon fiber adsorption, to recover harmful substances[132][133]. - The company has established a comprehensive safety production management system and conducted regular safety training and emergency drills[148]. Shareholder Engagement and Governance - The company reported a significant increase in revenue, achieving a total of 146.7 million shares voted in favor of key proposals during the shareholder meetings, representing 99.9991% approval[78]. - The company has maintained a high level of shareholder engagement, with 61.19% participation in the second temporary shareholder meeting[82]. - The company is committed to transparency, as evidenced by the unanimous approval of the 2022 annual report and profit distribution plan during the annual shareholder meeting[89]. - The company successfully passed the 2022 annual financial settlement report with unanimous support from shareholders, indicating strong confidence in financial management[89]. - The company approved the 2022 annual internal control self-assessment report with 100% of the voting shares in favor[94]. Future Plans and Investments - The company plans to use CNY 6,000 million of the raised funds for permanent working capital supplementation, completed by November 2022[56]. - The company has committed to invest CNY 15,500 million in the high-end pharmaceutical formulation internationalization project, expected to be completed by December 2024[53]. - The annual production capacity of the ibuprofen raw material project is set at 5,000 tons, with the expected completion date adjusted to June 2025 due to global economic and market conditions[52]. - Hendi Pharmaceutical plans to enter two new regional markets, aiming to increase its market share by 10% in these areas[200]. - The company is investing RMB 50 million in R&D for new drug formulations and innovative technologies in the upcoming fiscal year[200].